Evidence map›Paper›PMID 24574079›Full record

ArticleMolecular diagnosis & therapy2014

Dosage individualization of warfarin using artificial neural networks.

Mohammad I Saleh, Sameh Alzubiedi

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diagnosis & therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Mohammad I SalehFaculty of Pharmacy, The University of Jordan, Amman, 11942, Jordan, moh.saleh@ju.edu.jo.
Sameh Alzubiedi

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesOur objective was to explore artificial neural networks (ANNs) as a possible tool for dosage individualization of warfarin.

methodsDemographic, clinical, and genetic data were gathered from a previously collected cohort of patients with a stable warfarin dosage who were able to achieve an observed international normalized ratio of 2-3. Data from a cohort of 3,415 patients were used to develop an ANN dosing algorithm. Data from another cohort of 856 were used to validate the algorithm. The clinical significance of the ANN dosing algorithm was evaluated by calculating the percentage of patients whose predicted dosage of warfarin was within 20 % of the actual stable therapeutic dose. The clinical significance was also compared with a previously published dosing algorithm.

resultsA feed-forward neural network with three layers was able to successfully predict the ideal warfarin dosage in 48 % of the patients. The neural network model explained 48 % and 43 % of the dosage variability observed among patients in the derivation and validation cohorts, respectively. ANN analysis identified several predictors of warfarin dosage including race; age; height; weight; cytochrome P450 (CYP)2C9 genotype; VKORC1 genotype; sulfonamide, azole antifungals, or macrolide administration; carbamazepine, phenytoin, or rifampicin administration; and amiodarone administration.

conclusionAn ANN was applied to develop a warfarin dosing algorithm. The proposed dosing algorithm has the potential to recommend warfarin dosages that are close to the appropriate dosages.

Indexed as

Drug Dosage CalculationsNeural Networks, ComputerAdolescentAdultAgedAged, 80 and overAlgorithmsChildCohort StudiesFemaleHumansMaleMiddle AgedRegression AnalysisValidation Studies as TopicWarfarinWarfarin

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.